Korro Bio, Inc./$KRRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Korro Bio, Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Ticker

$KRRO
Sector
Primary listing

Employees

92

Korro Bio, Inc. Metrics

BasicAdvanced
$376M
-
-$9.76
-
-

Bulls say / Bears say

Korro’s lead program KRRO-110 received orphan drug designation from the European Medicines Agency on July 21, 2025, providing protocol assistance, reduced fees, and market exclusivity incentives for its AATD treatment (Nasdaq).
As of August 12, 2025, over 80% of planned healthy volunteer cohorts in the Phase 1/2a REWRITE study of KRRO-110 were dosed with no treatment-emergent serious adverse events or dose-limiting toxicities, demonstrating a favorable safety profile (Nasdaq).
Korro ended Q1 2025 with $139.0 million in cash, cash equivalents, and marketable securities, securing a financial runway into 2027 to support its RNA editing pipeline (Nasdaq).
In Q1 2025, Korro reduced its workforce by approximately 20% to streamline operations, a move that could undermine program execution and employee morale during critical development phases (Nasdaq).
Korro reported a net loss of $23.4 million for Q1 2025, up from $19.6 million in Q1 2024, indicating rising research and operational expenses without offsetting revenues (Nasdaq).
By June 30, 2025, cash, cash equivalents, and marketable securities declined to $119.6 million—down from $163.1 million at year-end 2024—potentially pressuring funding for upcoming trials and portfolio expansion (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KRRO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs